{
  "abstract": "Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.",
  "abstract_shown": true,
  "affiliations": [
    "CURE Drug Repurposing Collaboratory, Critical Path Institute , , ,",
    "Myalgic Encephalomyelitis Action Network , , ,",
    "Patient Led Research Collaborative , , ,",
    "Global Cures, Inc. , , ,",
    "Emory University School of Medicine , , ,",
    "Retired M.D. , , ,",
    "Stanford University School of Medicine , , ,"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Marco Schito"
    },
    {
      "affs": [
        0
      ],
      "name": "Stacey Coe"
    },
    {
      "affs": [
        1
      ],
      "name": "Jaime Seltzer"
    },
    {
      "affs": [
        2
      ],
      "name": "Hannah E. Davis"
    },
    {
      "affs": [
        3
      ],
      "name": "Vidula Sukhatme"
    },
    {
      "affs": [
        4
      ],
      "name": "Theodore W. Johnson II"
    },
    {
      "affs": [
        5
      ],
      "name": "Judy Stone"
    },
    {
      "affs": [
        4
      ],
      "name": "Alexander D. Truong"
    },
    {
      "affs": [
        6
      ],
      "name": "Linda N. Geng"
    },
    {
      "affs": [
        4
      ],
      "name": "Tiffany A. Walker"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0epen8rcp7fjr.bib",
  "cited_by": 0,
  "doi": "10.3389/fpubh.2026.1822376",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661906/?tool=EBI",
  "id": "0epen8rcp7fjr",
  "issns": [
    "2296-2565"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13661906",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2728|Long-Term Effects of COVID-19"
    ]
  ],
  "openalex": "W7214936642",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661906/pdf/?tool=EBI",
  "pmcid": "PMC13661906",
  "pmid": null,
  "published": "2026-09-30",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/0epen8rcp7fjr.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "PMC:PMC13661906",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13661906"
    },
    {
      "first_seen": "2026-10-30T12:20:22Z",
      "native_id": "10.3389/fpubh.2026.1822376",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fpubh.2026.1822376/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Long-Term Effects of COVID-19",
      "subfield": "neurology"
    }
  ],
  "title": "Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs",
  "title_text": "Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:22Z",
  "url": "https://research.draconitic.com/paper/0epen8rcp7fjr",
  "venue": "Frontiers in public health",
  "versions": []
}